ISPAD clinical practice consensus guidelines 2006-2007: Insulin treatment

Pediatric Diabetes

Volumn 8, Issue 2, 2007, Pages 88-102

  Bangstad, Hans Jacob ^a   Danne, Thomas ^b   Deeb, Larry C ^c   Jarosz Chobot, Przemyslawa ^d   Urakami, Tatsuhiko ^e   Hanas, Ragnar ^f  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b KINDERKRANKENHAUS AUF DER BULT   (Germany)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Department of Pediatric Endocrinology and Diabetes ^*  (Poland)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UDDEVALLA HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ANTIDIABETIC AGENT;

ARTICLE; BURNING SENSATION; CLINICAL TRIAL; COCHRANE LIBRARY; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG LABELING; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DRUG STORAGE; GLUCOSE BLOOD LEVEL; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; LIPOHYPERTROPHY; METERED DOSE INHALER; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHARPS DISPOSAL; SYRINGE; TREATMENT OUTCOME; DRUG EFFECT; FEMALE; MALE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE;

EID: 34247333782     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2007.00233.x     Document Type: Article

References (126)

1. Johnsson S. Retinopathy and nephropathy in diabetes mellitus: Comparison of the effects of two forms of treatment. Diabetes 1960: 9: 1-8.
2. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004: CD003287.
3. Brunner GA, Hirschberger S, Sendlhofer G et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000: 17: 371-375.
4. Danne T, Deiss D, Hopfenmuller W, Von Schutz W, Kordonouri O. Experience with insulin analogues in children. Horm Res 2002: 57 (Suppl. 1): 46-53.
5. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000: 159: 483-488.
6. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005: 28: 2100-2105.
7. Acerini CL, Cheetham TD, Edge JA, Dunger DB. Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia 2000: 43: 61-68.
8. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986: 315: 215-219.
9. Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002: 25: 2053-2057.
10. Ford-Adams ME, Murphy NP, Moore EJ et al. Insulin lispro: A potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 2003: 20: 656-660.
11. Deeb LC, Holcombe JH, Brunelle R et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001: 108: 1175-1179.
12. Tubiana-Rufi N, Coutant R, Bloch J et al. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: A randomized cross-over study. Horm Res 2004: 62: 265-271.
13. Tupola S, Komulainen J, Jaaskelainen J, Sipila I. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 2001: 18: 654-658.
14. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002: 24: 629-638.
15. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use Of Insulin Lispro In Continuous Subcutaneous Insulin Infusion Treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999: 22: 784-788.
16. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997: 100: 968-972.
17. Heller SR, Colagiuri S, Vaaler S et al. Hypoglycaemia with insulin aspart: A double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004: 21: 769-775.
18. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. European Insulin Aspart Study Group (In Process Citation). Diabet Med 2000: 17: 762-770.
19. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004: 53: 1614-1620.
20. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004: 47: 622-629.
21. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001: 24: 2005-2006.
22. Murphy NP, Keane SM, Ong KK et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003: 26: 799-804.
23. Porcellati F, Rossetti P, Pampanelli S et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004: 21: 1213-1220.
24. NICE (National Institute of Clinical Excellence). guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine. Technology Appraisal Guidance 2002: 53: http://guidance.nice.org.uk/TA53/guidance/pdf/English
25. Chase HP, Dixon B, Pearson J et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003: 143: 737-740.
26. Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003: 5: 801-806.
27. Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005: 115: 1320-1324.
28. Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge JA, Dunger DB. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000: 23: 557-559.
29. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007: 24: 27-34.
30. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003: 26: 3087-3092.
31. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003: 26: 590-596.
32. de Beaufort CE, Houtzagers CM, Bruining GJ et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: Two-year follow-up of a randomized, prospective trial. Diabet Med 1989: 6: 766-771.
33. DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994: 125: 177-188.
34. DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995: 44: 968-983.
35. Mortensen HB, Robertson KJ, Aanstoot HJ et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet Med 1998: 15: 752-759.
36. Dimeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004: 145: 380-384.
37. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomised controlled trials. BMJ 2002: 324: 705.
38. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003: 143: 796-801.
39. Kaufman FR. Intensive management of type 1 diabetes in young children. Lancet 2005: 365: 737-738.
40. Hanas R, Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatr Diabetes 2006: 7: 25-31.
41. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999: 22: 1779-1784.
42. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002: 141: 490-495.
43. Ahern JAH, Boland EA, Doane R et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 2002: 3: 10-15.
44. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003: 26: 1142-1146.
45. Saha ME, Huuppone T, Mikael K, Juuti M, Komulainen J. Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 1005-1010.
46. Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: Decreased HbA1c with low risk of hypoglycemia. J Pediatr Endocrinol Metab 2003: 16: 393-399.
47. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004: 27: 1554-1558.
48. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003: 20: 863-866.
49. Skogsberg L, Lindman E, Fors H. To compare metabolic control and quality of life (QoL) of CSII with multiple daily injections (MDI) in children/ adolescents at onset of T1DM. Pediatr Diabetes 2006: 7: 65 (Abstract).
50. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
51. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001: 139: 804-812.
52. Richter B, Neises G. 'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev 2005: CD003816.
53. Lauritzen T. Pharmacokinetic and clinical aspects of intensified subcutaneous insulin therapy. Dan Med Bull 1985: 32: 104-118.
54. Becker R, Frick A, Heinemann L, Nosek L, Rave K. Dose response relation of insulin glulisine (GLU) in subjects with type 1 diabetes (T1DM). Diabetes 2005: 54 (Suppl. 1): A332 (Abstract 1367-P).
55. Woodworth J, Howey D, Bowsher R, Lutz S, Sanat P, Brady P. Lys(B28), Pro(B29) Human Insulin (K): Dose ranging vs. Humulin R (H). Diabetologia 1993: 42 (Suppl. 1): 54A.
56. Nosek L, Heinemann L, Kaiser M, Arnolds S, Heise T. No increase in the duration of action with rising doses of insulin aspart. Diabetes 2003: 52 (Suppl. 1): A128 (Abstract 551-P).
57. Danne T, Aman J, Schober E et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003: 26: 2359-2364.
58. Stiller R, Kothny T, Gudat U et al. Intravenous administration of insulin lispro versus regular insulin in patients with type 1 diabetes. Diabetes 1999: 48 (Suppl. 1): A115 (Abstract 0497).
59. Heine RJ, Bilo HJ, Fonk T, van der Veen EA, van Der Meer J. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins. Diabetologia 1984: 27: 558-562.
60. Robertson K, Schoenle E, Gucev Z et al. Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: Lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia. Diabetes 2004: 51 (Suppl. 2): A144 (Abstract).
61. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000: 49: 2142-2148.
62. Dixon B, Peter Chase H, Burdick J et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005: 6: 150-154.
63. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (LANTUS): A multiple injection study in patients with type 1 diabetes. Diabet Med 2002: 19: 490-495.
64. Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003: 26: 1738-1744.
65. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000: 23: 639-643.
66. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005: 28: 1107-1112.
67. Mortensen H, Kocova M, Teng LY, Keiding J, Bruckner I, Philotheou A. Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes 2006: 7: 4-10.
68. Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 2005: 28: 1630-1635.
69. Stickelmeyer MP, Graf CJ, Frank BH, Ballard RL, Storms SM. Stability of U-10 and U-50 dilutions of insulin lispro. Diabetes Technol Ther 2000: 2: 61-66.
70. Jorgensen D, Solbeck H. Dilution of insulin aspart with NPH medium for small dose use in continuous subcutaneous insulin infusion does not affect in vitro stability. Diabetes 2005: 54 (Suppl. 1): A102 (Abstract).
71. Grajower MM, Fraser CG, Holcombe JH et al. How long should insulin be used once a vial is started? Diabetes Care 2003: 26: 2665-2666; discussion 2266-2669.
72. Rangawala S, Shah P, Hussain S, Goenka S, Pillai K. Insulin stored in matka (earthen pitcher) with water for 60 days does not reduce in bio-activity. J Pediatr Endocrinol Metab 1997: 10 (Suppl. 2): 347 (Abstract).
73. Mc Carthy JA, Covarrubias B, Sink P. Is the traditional alcohol wipe necessary before an insulin injection? Dogma disputed. Diabetes Care 1993: 16: 402.
74. Loeb JA, Herold KC, Barton KP, Robinson LE, Jaspan JB. Systematic approach to diagnosis and management of biphasic insulin allergy with local anti-inflammatory agents. Diabetes Care 1989: 12: 421-423.
75. Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with Type 1 diabetes. Diabetes Care 2002: 25: 634.
76. Arranz A, Andia V, Lopez-Guzman A. A case of lipoatrophy with Lispro insulin without insulin pump therapy. Diabetes Care 2004: 27: 625-626.
77. Beltrand J, Guilmin-Crepon S, Castanet M, Peuchmaur M, Czernichow P, Levy-Marchal C. Insulin allergy and extensive lipoatrophy in child with type 1 diabetes. Horm Res 2006: 65: 253-260.
78. Chantelau E, Lee DM, Hemmann DM, Zipfel U, Echterhoff S. What makes insulin injections painful? BMJ 1991: 303: 26-27.
79. Hanas R, Adolfsson P, Elfvin-Akesson K et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr 2002: 140: 315-320.
80. Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res 2006: 23: 37-43.
81. Ginsberg BH, Parkes JL, Sparacino C. The kinetics of insulin administration by insulin pens. Horm Metab Res 1994: 26: 584-587.
82. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994: 37: 377-380.
83. Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan LJ. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 1984: 7: 479-480.
84. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care 1993: 16: 1592-1597.
85. Frid A, Gunnarsson R, Guntner P, Linde B. Effects of accidental intramuscular injection on insulin absorption in IDDM. Diabetes Care 1988: 11: 41-45.
86. Frid A, Ostman J, Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care 1990: 13: 473-477.
87. Frid A. Injection and absorption of insulin. PhD Thesis, Faculty of Medicine, Karolinska Institute, Stockholm, Sweden, 1992.
88. Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): A fast-acting analoA of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999: 22: 1501-1506.
89. ter Braak EW, Woodworth JR, Bianchi R et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996: 19: 1437-1440.
90. Rave K, Heise T, Weyer C et al. Intramuscular versus subcutaneous injection of soluble and lispro insulin: Comparison of metabolic effects in healthy subjects. Diabet Med 1998: 15: 747-751.
91. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000: 23: 813-819.
92. Peter R, Luzio SD, Dunseath G et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care 2005: 28: 560-565.
93. Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med 2005: 22: 1444-1445.
94. Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract 1992: 16: 209-212.
95. Hofman P, Peart J, Holt J et al. Angled 6 mm needles and a pinch technique dramatically reduce intramuscular injections in children. J Pediatr Endocrinol Metab 2002: 15 (Suppl. 4): 1079 (Abstract).
96. Birkebaek NH, Johansen A, Solvig J. Cutis/subcutis thickness at insulin injection sites and localization of simulated insulin boluses in children with type 1 diabetes mellitus: Need for individualization of injection technique? Diabet Med 1998: 15: 965-971.
97. Smith CP, Sargent MA, Wilson BP, Price DA. Subcutaneous or intramuscular insulin injections. Arch Dis Child 1991: 66: 879-882.
98. Hanas SR, Ludvigsson J. Metabolic control is not altered when using indwelling catheters for insulin injections. Diabetes Care 1994: 17: 716-718.
99. Burdick P, Cooper S, Horner B et al. Use of the Insuflon™ injection port to improve glycemic control in children with type 1 diabetes. Diabetes 2006: 56 (Suppl. 1): A55 (Abstract 236).
100. Hanas SR, Carlsson S, Frid A, Ludvigsson J. Unchanged insulin absorption after 4 days' use of subcutaneous indwelling catheters for insulin injections. Diabetes Care 1997: 20: 487-490.
101. Hanas R, Ludvigsson J. Side effects and indwelling times of subcutaneous catheters for insulin injections: A new device for injecting insulin with a minimum of pain in the treatment of insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1990: 10: 73-83.
102. Diglas J, Feinböck C, Winkler F et al. Reduced pain perception with an automatic injection device for use with an insulin pen. Horm Res 1998: 50: A30 (Abstract).
103. Worth R, Anderson J, Taylor R, Alberti KG. Jet injection of insulin: comparison with conventional injection by syringe and needle. Br Med J 1980: 281: 713-714.
104. Chiasson JL, Ducros F, Poliquin-Hamet M, Lopez D, Lecavalier L, Hamet P. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 1984: 7: 331-337.
105. Houtzagers CM, Visser AP, Berntzen PA, Heine RJ, van der Veen EA. The Medi-Jector II: Efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia. Diabet Med 1988: 5: 135-138.
106. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005: 28: 15-19.
107. Blackett PR. Insulin pump treatment for recurrent ketoacidosis in adolescence. Diabetes Care 1995: 18: 881-882 (Letter).
108. Steindel BS, Roe TR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995: 27: 199-204.
109. NICE (National Institute of Clinical Excellence). Clinical and cost effectiveness of continuous subcutaneous insulin infusion for diabetes. Technology Appraisal 2003: 57: http://www.nice.org.uk/guidance/TA57
110. Guerci B, Benichou M, Floriot M et al. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care 2003: 26: 1137-1141.
111. Hanas R, Lundqvist K, Windell L. Blood glucose and beta-hydroxybutyrate responses when the insulin pump is stopped in children and adolescents. Pediatr Diabetes 2006: 7 (Suppl. 5): 35 (Abstract).
112. Bode B, Weinstein R, Bell D et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: A randomized study in type 1 diabetes. Diabetes Care 2002: 25: 439-444.
113. Siegmund T, Amelunxen S, Kaiser M, Schumm-Draeger P. Pump compatibility of insulin aspart compared to insulin Lispro with respect to catheter complications and dermal/subcutaneous irritations in patients (P) with type 1 diabetes (T1D) undergoing continuous subcutaneous insulin infusion (CSII) therapy. Diabetes 2005: 54 (Suppl. 1): A105 (Abstract).
114. Jarosz-Chobot P, Battelino T, Kordonouri O, Pankowska E, Danne T, Group PS. The PedPump survey: Indication for CSII and number of daily boluses are associated with HbA1c in 1086 children with T1 DM from 17 countries. Pediatr Diabetes 2005: 6 (Suppl. 3): 14 (Abstract).
115. Wysocki T, Harris MA, Mauras N et al. Absence of adverse effects of severe hypoglycemia on cognitive function in school-aged children with diabetes over 18 months. Diabetes Care 2003: 26: 1100-1105.
116. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999: 354: 1604-1607 (See comments).
117. Perriello G, Torlone E, Di Santo S et al. Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1988: 31: 811-815.
118. Halberg I, Jacobsen L, Dahl U. A study on self-mixing insulin aspart with NPH insulin in the syringe before injection. Diabetes 1999: 48 (Suppl. 1): A104 (Abstract 448).
119. Joseph SE, Korzon-Burakowska A, Woodworth JR, Evans M, Hopkins D, Janes JM, Amiel SA. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 1998: 21: 2098-2012.
120. Bastyr EJ III, Holcombe JH, Anderson JH, Clore JN. Mixing insulin lispro and ultralente insulin. Diabetes Care 1997: 20: 1047-1048.
121. Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004: 27: 2739-2740.
122. Fiallo-Scharer R, Chase P, Horner B, Mc Fann K, Walravens P, Garg S. The mixing of rapid-acting insulin (RAI) analogues (Humalog ® or NovoLog ®) with insulin glargine (IG) in youth with type 1 diabetes (T1D). Diabetes 2005: 54 (Suppl. 1): A451 (Abstract 1879-P).
123. Tan CY, Wilson DM, Buckingham B. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2004: 5: 80-86.
124. Conrad SC, Mc Grath MT, Gitelman SE. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr 2002: 140: 235-240.
125. Boland E, Ahern J, Vincent M. Pumps and kids: Basal requirements for excellent metabolic control. Diabetes 2002: 51 (Suppl. 2): A3 (Abstract).
126. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: A controlled crossover study. Pediatrics 2003: 111: 933-938.